Renaissance Technologies LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the first quarter, according to its most recent filing with the SEC. The firm purchased 382,400 shares of the biopharmaceutical company’s stock, valued at approximately $746,000. Renaissance Technologies LLC owned about 0.46% of Catalyst Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $1,170,000. Bank of New York Mellon Corp raised its position in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 2,404 shares during the period. Oxford Asset Management raised its position in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 34,181 shares during the period. JPMorgan Chase & Co. purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $155,000. Finally, Knott David M purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $554,000. Hedge funds and other institutional investors own 40.20% of the company’s stock.

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) traded up 2.57% during trading on Tuesday, hitting $2.79. 124,708 shares of the stock were exchanged. The firm’s market capitalization is $235.91 million. Catalyst Pharmaceuticals, Inc. has a 52 week low of $0.94 and a 52 week high of $3.20. The firm has a 50 day moving average price of $2.88 and a 200 day moving average price of $2.10.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Analysts forecast that Catalyst Pharmaceuticals, Inc. will post ($0.23) EPS for the current fiscal year.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/29/renaissance-technologies-llc-invests-746000-in-catalyst-pharmaceuticals-inc-cprx.html.

A number of equities analysts have commented on CPRX shares. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Monday, May 22nd. Piper Jaffray Companies set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 7th. Finally, Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 10th.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Stock Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.